About 1,040,000 results
Open links in new tab
De Novo Metastatic Prostate Cancer: Are We Moving toward a ...
De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5–10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the …
Survival in Patients With De Novo Metastatic Prostate Cancer
Mar 12, 2024 · Overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) has improved in clinical trials over the last 20 years. 1,2 It is unclear whether new treatments …
Management of de Novo Metastatic Hormone-Sensitive Prostate ...
Sep 9, 2024 · Prostate cancer treatments paradigms are in continuous evolution, especially in the metastatic setting. In this context, the Genito-Urinary Group of Italian Association of …
Updated treatment recommendations for prostate cancer from ...
Mar 21, 2023 · ADT–docetaxel–abiraterone–prednisone is recommended as first-line treatment for fit men with de novo metastatic hormone-sensitive prostate cancer (mHSPC), especially in …